• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    1/8/24 1:36:30 PM ET
    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMAM alert in real time by email

    Shares of RxSight, Inc. (NASDAQ:RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates.

    Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.

    RxSight shares jumped 20% to $44.31 on Monday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Harpoon Therapeutics, Inc. (NASDAQ:HARP) shares jumped 111.2% to $22.28 after Merck announced it will acquire the company for $23 per share in cash.
    • Ambrx Biopharma Inc. (NASDAQ:AMAM) jumped 98.1% to $27.00 after Johnson & Johnson announced it will acquire the company in an all-cash merger for a total equity value of approximately $2 billion.
    • Spectaire Holdings Inc. (NASDAQ:SPEC) jumped 75.2% to $2.96.
    • Nkarta, Inc. (NASDAQ:NKTX) rose 51% to $9.17 as the company announced updated corporate presentation to reflect business and strategic update.
    • Universe Pharmaceuticals INC (NASDAQ:UPC) gained 42% to $2.22.
    • Elevation Oncology, Inc. (NASDAQ:ELEV) jumped 39.2% to $1.2193.
    • NexImmune, Inc. (NASDAQ:NEXI) rose 34.7% to $8.32.
    • Praxis Precision Medicines, Inc. (NASDAQ:PRAX) rose 34% to $33.76 as the company issued update on advancing clinical stage portfolio.
    • QuantaSing Group Limited (NASDAQ:QSG) gained 31% to $2.0563.
    • Butterfly Network, Inc. (NASDAQ:BFLY) rose 29.7% to $1.31 as the company announced FDA clearance of handheld ultrasound system, Butterfly iQ3.
    • Venus Concept Inc. (NASDAQ:VERO) climbed 28% to $1.51.
    • Ardelyx, Inc. (NASDAQ:ARDX) gained 25.5% to $7.73 after the company provided an update on its progress in 2023 and initial expectations for 2024.
    • BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose 20.8% to $7.36 after the company issued preliminary Q4 revenue guidance above estimates. Also the company said it is approaching positive EPS and cash flow in 2H 2025.
    • Axonics, Inc. (NASDAQ:AXNX) jumped 19.9% to $69.03 after the company announced a deal to be acquired by Boston Scientific.
    • Crocs, Inc. (NASDAQ:CROX) jumped 18.8% to $102.69 after the company issued strong Q4 and full year 2023 guidance.
    • LendingTree, Inc. (NASDAQ:TREE) rose 17.3% to $33.50.
    • Wolverine World Wide, Inc. (NYSE:WWW) jumped 16.7% to $9.02. Wolverine Worldwide affirmed preliminary 2023 financial results in line with guidance.
    • Ampio Pharmaceuticals, Inc. (NYSE:AMPE) gained 16.4% to $2.0799 after falling around 8% on Friday.
    • Shattuck Labs, Inc. (NASDAQ:STTK) gained 15.2% to $9.52.
    • Vincerx Pharma, Inc. (NASDAQ:VINC) shares rose 14.3% to $1.36 after the company announced compelling clinical efficacy of enitociclib in combination with venetoclax and prednisone in lymphoma.
    • Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) shares gained 14.1% to $2.84 after jumping over 10% on Friday.
    • Silk Road Medical, Inc (NASDAQ:SILK) rose 13.4% to $12.91.
    • OPKO Health, Inc. (NASDAQ:OPK) jumped 12.5% to $1.00.
    • Avadel Pharmaceuticals plc (NASDAQ:AVDL) gained 12% to $16.68 after the company issued a business update.
    • Fastly, Inc. (NYSE:FSLY) jumped 10.5% to $17.88 after RBC Capital upgraded the stock from Underperform to Sector Perform and raised its price target from $12 to $18.
    • Upwork Inc. (NASDAQ:UPWK) gained 10.3% to $15.51 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $13 to $20.
    • Commercial Metals Company (NYSE:CMC) rose 6.2% to $51.21 following strong quarterly results.

    Losers

    • LumiraDx Limited (NASDAQ:LMDX) shares fell 45.5% to $0.0187. LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th.
    • Top KingWin Ltd (NASDAQ:TCJH) dipped 38.8% to $1.18.
    • Solo Brands, Inc. (NYSE:DTC) dipped 38.7% to $3.6150 after the company lowered full year 2023 revenue guidance below estimates.
    • Dada Nexus Limited (NASDAQ:DADA) shares dipped 38.1% to $1.95. Dada Nexus said in the course of its routine internal audit, certain suspicious practices were identified that may cast doubt on certain revenues from the company's online advertising and marketing services in 2023.
    • Prothena Corporation plc (NASDAQ:PRTA) fell 25.1% to $30.45 after the company issued updates on PRX012, PRX123, Birtamimab and Portfolio programs.
    • Jin Medical International Ltd. (NASDAQ:ZJYL) fell 23.4% to $95.00.
    • MMTec, Inc. (NASDAQ:MTC) fell 22.4% to $1.82.
    • Evolve Transition Infrastructure LP (NASDAQ:SNMP) tumbled 20.8% to $1.33.
    • Revance Therapeutics, Inc. (NASDAQ:RVNC) fell 20.1% to $6.68 after the company issued preliminary Q4 and FY23 financial results and guidance.
    • Banzai International, Inc. (NASDAQ:BNZI) shares fell 19.3% to $2.07. Banzai shares jumped around 55% on Friday after the company signed an LOI to acquire IGLeads.
    • Northern Dynasty Minerals Ltd. (NYSE:NAK) dipped 18.8% to $0.3107.
    • The Arena Group Holdings, Inc. (NYSE:AREN) shares fell 18.2% to $1.7603 after dipping 17% on Friday.
    • The Arena Group Holdings, Inc. (NASDAQ:AREN) dipped 18% to $ 1.7650.
    • Inspire Veterinary Partners, Inc. (NASDAQ:IVP) declined 16.8% to $0.1881. Inspire Veterinary Partners recently filed a prospectus related to up to a $5 million public offering
    • Pacific Biosciences of California, Inc. (NASDAQ:PACB) fell 15.1% to $7.99. Pacific Biosciences of California said it sees preliminary FY23 revenue of $200.5 million.
    • REGENXBIO Inc. (NASDAQ:RGNX) fell 14.8% to $14.01. US District Court issued decision on REGENXBIO and University of Pennsylvania NAV technology patent infringement lawsuit.
    • Revance Therapeutics, Inc. (NASDAQ:RVNC) fell 13.6% to $7.21. Revance issued corporate update, preliminary Q4 and FY23 financial results, and financial outlook.
    • BioSig Technologies, Inc. (NASDAQ:BSGM) fell 13.6% to $0.35. On Jan. 5, BioSig Technologies received a letter from Nasdaq notifying company has regained compliance with Nasdaq Listing Rule 5550(b)(2).
    • Bright Health Group, Inc. (NYSE:BHG) dipped 12.8% to $10.00.
    • Safe and Green Development Corporation (NASDAQ:SGD) shares fell 11.3% to $1.80 after jumping 49% on Friday.
    • Argo Blockchain plc (NASDAQ:ARBK) fell 11.1% to $3.11 after announcing £7.8 million ($9.9 million) placing.
    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) dipped 10.7% to $0.5146. Shuttle Pharmaceuticals received FDA approval to proceed with Phase II clinical trial of ropidoxuridine for the treatment of patients with glioblastoma.
    • Paragon 28, Inc. (NYSE:FNA) fell 9.6% to $11.83. Paragon 28 said it sees preliminary fourth-quarter revenue of $60.3 million to $60.6 million.
    • Sharps Technology, Inc. (NASDAQ:STSS) fell 8.3% to $0.4032 after jumping 12% on Friday.
    • Dynavax Technologies Corporation (NASDAQ:DVAX) dipped 7.5% to $13.63. Dynavax sees preliminary 2023 HEPLISAV-B vaccine net product revenue of $213 million.
    • The Boeing Company (NYSE:BA) fell 7% to $231.69 after an exit door blew out of a 737 aircraft during a commercial flight.
    • Spirit AeroSystems Holdings, Inc. (NYSE:SPR) fell 6.5% to $29.67 after an exit door blew out of a 737 aircraft during a commercial flight. Spirit Aerosystems was a vendor involved with the faulty door.

     

    Now Read This: Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'

    Get the next $AMAM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMAM
    $AMPE
    $ARBK
    $ARDX

    CompanyDatePrice TargetRatingAnalyst
    LendingTree Inc.
    $TREE
    4/14/2026$50.00Overweight
    Analyst
    Fastly Inc.
    $FSLY
    4/14/2026$24.00Outperform
    Evercore ISI
    Fastly Inc.
    $FSLY
    4/14/2026$24.00Buy → Hold
    Craig Hallum
    Crocs Inc.
    $CROX
    4/14/2026$135.00Neutral → Buy
    Seaport Research Partners
    Praxis Precision Medicines Inc.
    $PRAX
    4/10/2026$815.00Strong Buy
    Raymond James
    Commercial Metals Company
    $CMC
    4/1/2026$74.00Neutral
    Goldman
    Boeing Company
    $BA
    4/1/2026$250.00Overweight
    Wells Fargo
    Wolverine World Wide Inc.
    $WWW
    3/26/2026$21.00Buy
    Needham
    More analyst ratings

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Buckley Mortimer J bought $499,966 worth of shares (2,230 units at $224.20), increasing direct ownership by 101% to 4,430 units (SEC Form 4)

    4 - BOEING CO (0000012927) (Issuer)

    3/5/26 4:59:07 PM ET
    $BA
    Aerospace
    Industrials

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Arriola Dennis V bought $149,380 worth of shares (2,000 units at $74.69), increasing direct ownership by 28% to 9,238 units (SEC Form 4)

    4 - COMMERCIAL METALS Co (0000022444) (Issuer)

    1/22/26 10:15:04 AM ET
    $CMC
    Steel/Iron Ore
    Industrials

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Arena Group to Host First Quarter 2026 Financial Results Conference Call on Friday, May 8, 2026

    Company Invites Shareholders to Submit Questions in Advance The Arena Group Holdings, Inc. (NYSE:AREN), the brand, data and IP company that builds, acquires and scales high-performing digital assets—home to many of the nation's most recognizable brands including TheStreet, Parade, Men's Journal, Athlon Sports, Surfer, ShopHQ and more—today announced that it will release its financial results for the first quarter ended March 31, 2026, on Friday, May 8, 2026, in advance of the open of the market. Conference Call and Webcast Details Paul Edmondson, The Arena Group's Chief Executive Officer and Geoffrey Wait, Principal Financial Officer will host a conference call and live webcast to rev

    4/24/26 8:30:00 AM ET
    $AREN
    EDP Services
    Technology

    Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

    WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract, exploring the patient characteristics associated with irritable bowel syndrome with constipation (IBS-C) treatment patterns and their impact on gastrointestinal (GI) related healthcare resource utilization (HCRU), has been accepted as a poster presentation at the upcoming Digestive Disease Week Conference (DDW), to be held May 2-5, 2026, in Chicago. Information regarding DDW can be found here. Patient Factors Associated wi

    4/23/26 8:01:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Western Roots, Wild Soles: Chaco and Wrangler Pair up for Adventurous Apparel and Footwear Collection

    Made for the ranch to the river, this collection features coordinating shoes and shirts that will carry you on every journey. Chaco and Wrangler® have joined forces to bring their Western roots and wild soles together. Celebrating a shared commitment to durability and authenticity, these two brands have created an eight-piece unisex collection built for adventure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423800470/en/Chaco x Wrangler The Chaco x Wrangler® collaboration perfectly aligns with the values of active outdoor enthusiasts, particularly among Gen Z and Millennials—who demand lasting construction from their fav

    4/23/26 8:00:00 AM ET
    $KTB
    $WWW
    Garments and Clothing
    Industrials
    Shoe Manufacturing
    Consumer Discretionary

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    SEC Filings

    View All

    SEC Form 6-K filed by Northern Dynasty Minerals Ltd.

    6-K - NORTHERN DYNASTY MINERALS LTD (0001164771) (Filer)

    4/23/26 7:00:23 PM ET
    $NAK
    Precious Metals
    Basic Materials

    SEC Form DEFA14A filed by Pacific Biosciences of California Inc.

    DEFA14A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    4/23/26 4:43:04 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Nkarta Inc.

    DEFA14A - Nkarta, Inc. (0001787400) (Filer)

    4/23/26 4:41:50 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Guo Yanru

    3 - Jin Medical International Ltd. (0001837821) (Issuer)

    4/24/26 10:44:35 AM ET
    $ZJYL
    Industrial Specialties
    Health Care

    New insider Wang Erqi claimed ownership of 4,306,307 units of Class A Ordinary Shares and claimed ownership of 1,000,000 units of Class B Ordinary Shares (SEC Form 3)

    3 - Jin Medical International Ltd. (0001837821) (Issuer)

    4/24/26 10:43:55 AM ET
    $ZJYL
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Wang Ziqiang

    3 - Jin Medical International Ltd. (0001837821) (Issuer)

    4/24/26 10:42:49 AM ET
    $ZJYL
    Industrial Specialties
    Health Care

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst resumed coverage on LendingTree with a new price target

    Analyst resumed coverage of LendingTree with a rating of Overweight and set a new price target of $50.00

    4/14/26 8:24:09 AM ET
    $TREE
    Finance: Consumer Services
    Finance

    Evercore ISI initiated coverage on Fastly with a new price target

    Evercore ISI initiated coverage of Fastly with a rating of Outperform and set a new price target of $24.00

    4/14/26 8:21:14 AM ET
    $FSLY
    Computer Software: Prepackaged Software
    Technology

    Fastly downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Fastly from Buy to Hold and set a new price target of $24.00

    4/14/26 8:15:14 AM ET
    $FSLY
    Computer Software: Prepackaged Software
    Technology

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Leadership Updates

    Live Leadership Updates

    View All

    Butterfly Network Appoints Arun Nagdev, MD as Chief Medical Officer – POCUS

    Prominent POCUS thought leader joins to advance clinical strategy and further Butterfly's mission to democratize ultrasound worldwide. Butterfly Network (NYSE:BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of Arun Nagdev, MD as Chief Medical Officer – Point-of-Care Ultrasound (POCUS). In this role, Dr. Nagdev will lead the global medical strategy for the Company's core POCUS business, advancing clinical product validation, strengthening customer engagement, and supporting regulatory and clinical development efforts. Dr. Nagdev brings more than 20 years of experience advancing POCUS adoption, educ

    4/21/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

    WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W. Ettenberg, a seasoned leader with more than 25 years of legal experience in the biopharmaceutical industry, as Chief Legal Officer (CLO). She will oversee Ardelyx's legal, compliance, regulatory, and government affairs operations. Ms. Ettenberg succeeds Elizabeth Grammer, who has chosen to retire after an extraordinary 16-year career at the company. "I am thrilled to welcome Felecia as our new Chief Legal Officer," said Mik

    4/20/26 8:00:00 AM ET
    $ARDX
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CMC Announces Appointment of Michael "Mike" Dumais to Board of Directors

    IRVING, Texas, April 13, 2026 /PRNewswire/ -- CMC (NYSE:CMC) ("CMC" or the "Company") today announced that it has named Michael "Mike" Dumais to the Company's Board of Directors (the "Board"), effective June 23, 2026. Mr. Dumais brings more than 30 years of leadership experience across industrial operations and corporate strategy. Most recently, he served as Executive Vice President and Chief Transformation Officer at Raytheon Technologies Corporation, where he led enterprise-wide transformation initiatives following the merger of United Technologies Corporation and Raytheon Com

    4/13/26 4:15:00 PM ET
    $CMC
    Steel/Iron Ore
    Industrials

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nkarta Inc.

    SC 13G - Nkarta, Inc. (0001787400) (Subject)

    12/13/24 5:02:47 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Upwork Inc.

    SC 13G/A - UPWORK, INC (0001627475) (Subject)

    12/9/24 6:02:26 AM ET
    $UPWK
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Financials

    Live finance-specific insights

    View All

    The Arena Group to Host First Quarter 2026 Financial Results Conference Call on Friday, May 8, 2026

    Company Invites Shareholders to Submit Questions in Advance The Arena Group Holdings, Inc. (NYSE:AREN), the brand, data and IP company that builds, acquires and scales high-performing digital assets—home to many of the nation's most recognizable brands including TheStreet, Parade, Men's Journal, Athlon Sports, Surfer, ShopHQ and more—today announced that it will release its financial results for the first quarter ended March 31, 2026, on Friday, May 8, 2026, in advance of the open of the market. Conference Call and Webcast Details Paul Edmondson, The Arena Group's Chief Executive Officer and Geoffrey Wait, Principal Financial Officer will host a conference call and live webcast to rev

    4/24/26 8:30:00 AM ET
    $AREN
    EDP Services
    Technology

    RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6

    ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link s

    4/22/26 4:10:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Boeing Reports First Quarter Results

    ARLINGTON, Va., April 22, 2026 /PRNewswire/ --  First Quarter 2026Revenue increased to $22.2 billion primarily reflecting 143 commercial deliveriesGAAP loss per share of ($0.11) and core loss per share (non-GAAP)* of ($0.20)Operating cash flow of ($0.2) billion and free cash flow (non-GAAP)* of ($1.5) billionTotal company backlog grew to a record $695 billion, including over 6,100 commercial airplanesTable 1. Summary Financial ResultsFirst Quarter(Dollars in Millions, except per share data)20262025ChangeRevenues$22,217$19,49614 %GAAPEarnings from operations$448$461(3) %Operating margins2.0 %2.4 %(0.4) PtsNet loss($7)($31)NMDiluted loss per share($0.11)($0.16)NMOperating cash flow($179)($1,61

    4/22/26 7:30:00 AM ET
    $BA
    Aerospace
    Industrials